Senores Pharmaceuticals, Inc (SPI), a wholly owned subsidiary of Senores Pharmaceuticals Limited, has announced the execution of a strategic Operating Agreement on April 2, 2026, marking a major milestone in its international growth strategy. The agreement establishes a joint venture entity, Amerisyn, LLC, positioning the company to enter and expand within the U.S. government procurement market.
The formation of Amerisyn creates a strategic platform for Senores to supply its pharmaceutical portfolio to U.S. federal agencies, including veterans’ healthcare systems and defense-related institutions. The joint venture structure enhances eligibility for government contracts and enables participation in long-term supply programs requiring specialized compliance and credentials.
This development represents a significant step forward in Senores’ global expansion, particularly in accessing high-barrier markets with stringent regulatory and operational requirements. By leveraging its manufacturing expertise and established product pipeline, the company aims to strengthen its presence in institutional and government healthcare supply chains.
Commenting on the development, Swapnil Shah, Managing Director of Senores Pharmaceuticals Limited, stated that the joint venture is expected to drive substantial growth in international business volumes while unlocking new opportunities in the US federal sector.
Senores Pharmaceuticals Limited is a research-driven pharmaceutical organization engaged in the development and manufacturing of a diverse portfolio of products across regulated and emerging markets. The company currently maintains an extensive pipeline of Abbreviated New Drug Applications (ANDAs), along with a strong presence in contract manufacturing and development (CMO/CDMO) services.
Senores operates multiple manufacturing facilities, including a USFDA-approved plant in Atlanta compliant with DEA, TAA, and BAA requirements, as well as facilities in Baroda and Ahmedabad catering to global and emerging markets. Its API manufacturing units and advanced R&D centers across the USand India support innovation and product differentiation.
With a presence in over 40 countries and approvals from multiple regulatory authorities, Senores continues to expand its global footprint. The Amerisyn joint venture reinforces its commitment to delivering high-quality pharmaceutical solutions while strengthening its strategic positioning in one of the world’s most competitive healthcare markets.
